Apr 23, 2002
Citations
0
Influential Citations
5
Citations
Quality indicators
Journal
Circulation
Abstract
Losartan potassium (Cozaar), manufactured by Merck and Company, Inc, was proposed for the prevention of progression of nephropathy in patients with type II diabetes. Losartan is an angiotensin II receptor blocker (ARB) previously approved for the treatment of hypertension. It was examined in the Reduction of Endpoints in NIDDM with Angiotensin II Antagonist Losartan (RENAAL) study of 1513 normotensive/hypertensive patients with type II diabetes and nephropathy. At baseline, these patients had mean systolic and diastolic blood pressures of 152 mm Hg and 82 mm Hg, respectively, a mean creatinine of 1.9 mg/dL, and a mean proteinuria (UA/Cr) of 1808 mg/g Cr. Although patients could have received an ACE inhibitor or ARB in the past, no such treatment was allowed for the enrolled patients during the course of the trial. The …